Neurosense Therapeutics is trading at $1.45, up 13.28%, amid biotech-sector strength and broader risk-on sentiment.
- No clear company-specific announcement explaining the November 4 move was identified; a market listing showed no company headlines that day.
- Supplied sector data showed XBI up 2.05%; the midterm-election outcome was associated with a U.S. market rally.
- A positive Alzheimer’s biomarker report appeared under a November 4 listing, but article text dates it June 26 and does not link it to the share move.